Abbott Laboratories (NYSE: ABT) reported Q2 EPS of $1.12, $0.01 better than the analyst estimate of $1.11. Revenue for the quarter came in at $9.62 billion versus the consensus estimate of $9.56 billion.

Sees FY2011 EPS of $4.58-$4.68, versus prior guidance of $4.54-$4.64 and the consensus of $4.60.

Earnings Guidance Hot Guidance